Search

Your search keyword '"Kosiorek, Heidi E."' showing total 646 results
Start Over Author "Kosiorek, Heidi E."
646 results on '"Kosiorek, Heidi E."'

201. Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Author

Scherber, Robyn M., primary, Geyer, Holly, additional, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Kiladjian, Jean-Jacques, additional, Slot, Stefanie, additional, Zweegman, Sonja, additional, Te Boekhorst, Peter, additional, Commandeur, Suzan, additional, Schouten, Harry C., additional, Sackmann, Federico, additional, Fuentes, Ana Kerguelen, additional, Hernandez-Maraver, Dolores, additional, Pahl, Heike L, additional, Griesshammer, Martin, additional, Stegelmann, Frank, additional, Doehner, Konstanze, additional, Lehmann, Thomas, additional, Bonatz, Karen, additional, Reiter, Andreas, additional, Boyer, Francoise, additional, Etienne, Gabriel, additional, Ianotto, Jean Christophe, additional, Ranta, Dana, additional, Roy, Lydia, additional, Cahn, Jean-Yves, additional, Harrison, Claire N., additional, Radia, Deepti, additional, Muxi, Pablo J., additional, Maldonado, Norman I, additional, Besses, Carlos, additional, Cervantes, Francisco, additional, Johansson, Peter L., additional, Barbui, Tiziano, additional, Barosi, Giovanni, additional, Vannucchi, Alessandro M., additional, Passamonti, Francesco, additional, Andreasson, Bjorn, additional, Ferrari, Maria, additional, Rambaldi, Alessandro, additional, Samuelsson, Jan, additional, Cannon, Keith, additional, Sun, Xiujuan, additional, Xu, Junqing, additional, Zhang, Peihong, additional, Xu, Zefeng, additional, and Mesa, Ruben A., additional

Published
2016
Full Text
View/download PDF

202. Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia

Author

Mascarenhas, John O., primary, Prchal, Josef T., additional, Rambaldi, Alessandro, additional, Mesa, Ruben A., additional, Berenzon, Dmitriy, additional, Yacoub, Abdulraheem, additional, Harrison, Claire N., additional, McMullin, Mary Frances, additional, Vannucchi, Alessandro M., additional, Ewing, Joanne C, additional, O'Connell, Casey L, additional, Kiladjian, Jean-Jacques, additional, Mead, Adam, additional, Winton, Elliott F., additional, Leibowitz, David S., additional, De Stefano, Valerio, additional, Arcasoy, Murat O., additional, Kessler, Craig M., additional, Catchatorian, Rosalind, additional, Rondelli, Damiano, additional, Silver, Richard T., additional, Ritchie, Ellen K., additional, Nagler, Arnon, additional, Kremyanskaya, Marina, additional, Schlenk, Richard F., additional, Weinberg, Rona Singer, additional, Salama, Mohamed E, additional, Tognoni, Gianni, additional, Prosperini, Giuseppe, additional, Di Lelio, Alessandra, additional, Serone, Eliseo, additional, Marfisi, Lorenzo, additional, Kleczko, Jill, additional, Kosiorek, Heidi E., additional, Barbui, Tiziano, additional, Dueck, Amylou C., additional, and Hoffman, Ronald, additional

Published
2016
Full Text
View/download PDF

203. Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Author

Jain, Tania, primary, Kung, Shu Ting, additional, Shah, Vishal, additional, Dueck, Amylou Constance, additional, Kosiorek, Heidi E., additional, Mikhael, Joseph, additional, Bergsagel, P. Leif, additional, Reeder, Craig B., additional, Noel, Pierre, additional, Adams, Roberta H., additional, Luft, Susan, additional, Mayo, Angela, additional, Stewart, A. Keith, additional, and Fonseca, Rafael, additional

Published
2016
Full Text
View/download PDF

205. Trends in mastectomy and reconstruction for breast cancer; a twelve year experience from a tertiary care center

Author

Chang, James M., primary, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Casey, William J., additional, Rebecca, Alanna M., additional, Mahabir, Raman, additional, Patel, Samir H., additional, Keole, Sameer R., additional, Wong, William W., additional, Vargas, Carlos E., additional, Halyard, Michele Y., additional, Gray, Richard J., additional, Wasif, Nabil, additional, Stucky, Chee-Chee H., additional, and Pockaj, Barbara A., additional

Published
2016
Full Text
View/download PDF

206. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts

Author

Scherber, Robyn Marie, primary, Geyer, Holly Lynn, additional, Dueck, Amylou C., additional, Kosiorek, Heidi E., additional, Finazzi, Guido, additional, Cavazzina, Riccardo, additional, Masciulli, Arianna, additional, Scarano, Marco, additional, Vannucchi, Alessandro M., additional, Mesa, Ruben A., additional, and Barbui, Tiziano, additional

Published
2016
Full Text
View/download PDF

208. Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis.

Author

Brewer, Ann C., Huber, Jordan T., Girardo, Marlene E., Kosiorek, Heidi E., Burns, Mark W., Blair, Janis E., and Stewart, Terry D.

Abstract

Background: Fluconazole is the most commonly used antifungal treatment for various forms of coccidioidomycosis. Although we had anecdotally observed a high proportion of patients reporting cutaneous adverse effects associated with fluconazole treatment, this observation was not well described in the medical literature, and we were unsure of the additional effect of the arid desert environment of Arizona. Methods: We performed a one‐time, voluntary survey of patients with coccidioidomycosis and compared the responses of patients treated with fluconazole with those of untreated patients. Results: From January 1, 2015, to August 22, 2017, 62 fluconazole‐treated and 35 untreated patients with coccidioidomycosis provided consent and were enrolled in the study; demographics were similar between the two groups. Among the 62 fluconazole‐treated patients, daily dosages ranged from 200 mg to 800 mg. However, most (44/62, 71%) took 400 mg daily, the typical dose for the treatment of coccidioidomycosis. The median fluconazole treatment duration at the time of study participation was 6 months. When compared with untreated patients, those taking fluconazole had more moderate to severe dry lips (74.2% [46/62] vs. 23.5% [8/34]; P < 0.001), dry skin (45.8% [27/59] vs. 22.9% [8/35]; P = 0.03), and alopecia (31.1% [19/61] vs. 11.4% [4/35]; P = 0.004). Conclusions: For the treatment of coccidioidomycosis, patients receiving fluconazole reported significantly more severe cutaneous effects, including dry lips, dry skin, and alopecia, than untreated patients. Our findings identify an association but do not prove causality. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

209. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.

Author

Jain, Tania, Kosiorek, Heidi E., Grys, Thomas E., Kung, Shu Ting, Shah, Vishal S., Betcher, Jeffrey A., Slack, James L., Leis, Jose F., Khera, Nandita, Noel, Pierre, Palmer, Jeanne M., and Sproat, Lisa Z.

Subjects
*CELL transplantation, *EPSTEIN-Barr virus
Abstract

Epstein-Barr virus (EBV) reactivation is an unresolved medical issue after allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab treatment is recommended for EBV reactivation after HSCT but the number of doses of rituximab to use is unclear. In this study, risk factors and outcomes of patients who needed 1 dose vs >1 doses of preemptive rituximab to clear EBV viremia were compared. A higher viral load was more likely to be associated with higher doses of rituximab. Patients whose EBV viremia cleared with 1 dose of rituximab were more likely to have a preceding reduction of immunosuppression. Overall survival (OS) in these 2 cohorts was not different (18.7 vs 26.6 months, respectively, p = .96). Since rituximab can have side effects and is fairly costly, a predictive model to determine the number of rituximab doses using viral load would be a useful and cost-effective manner to utilize rituximab for this indication. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

210. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy.

Author

Hilal, Talal, Covington, Matthew, Kosiorek, Heidi E., Zwart, Christine, Ocal, Idris T., Pockaj, Barbara A., Northfelt, Donald W., and Patel, Bhavika K.

Subjects
BREAST tumor diagnosis, BREAST tumor treatment, BREAST tumors, COMBINED modality therapy, DIAGNOSTIC imaging, MAGNETIC resonance imaging, RADIOLOGISTS, ULTRASONIC imaging, PHENOTYPES, PILOT projects, GENETICS
Abstract

Neoadjuvant endocrine therapy (NET) is increasingly used for the treatment of estrogen receptor positive, HER2 negative breast cancer. We evaluated whether MRI phenotype and background parenchymal enhancement (BPE) can predict response to NET. Patients with localized breast cancer treated with NET and had a pre‐treatment breast MRI were identified. Baseline MRI phenotype and BPE was interpreted by a single radiologist blinded to the results of systemic therapy. Response was defined as stable disease or reduction in tumor size on clinical and/or ultrasound examination. Of the 21 patients identified, 17 were responders; all patients with minimal/mild BPE had a response compared to 5/9 (56%) patients with moderate/marked BPE (P = 0.02). All four nonresponders had moderate/marked BPE as compared to 5/17 (29%) responders (P = 0.02). This pilot study suggests that minimal/mild BPE may be predictive of a positive response to NET. A higher degree of background enhancement was significantly predictive of negative response to NET. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

211. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life : An analysis by the MPN QOL International Study Group

Author

Geyer, Holly L., Andreasson, Bjorn, Kosiorek, Heidi E., Dueck, Amylou C., Scherber, Robyn M., Martin, Kari A., Butler, Kristina A., Harrison, Claire N., Radia, Deepti H., Cervantes, Francisco, Kiladjian, Jean-Jacques, Reiter, Andreas, Birgegård, Gunnar, Passamonti, Francesco, Senyak, Zhenya, Vannucchi, Alessandro M., Paoli, Chiara, Xiao, Zhijian, Samuelsson, Jan, Mesa, Ruben A., Geyer, Holly L., Andreasson, Bjorn, Kosiorek, Heidi E., Dueck, Amylou C., Scherber, Robyn M., Martin, Kari A., Butler, Kristina A., Harrison, Claire N., Radia, Deepti H., Cervantes, Francisco, Kiladjian, Jean-Jacques, Reiter, Andreas, Birgegård, Gunnar, Passamonti, Francesco, Senyak, Zhenya, Vannucchi, Alessandro M., Paoli, Chiara, Xiao, Zhijian, Samuelsson, Jan, and Mesa, Ruben A.

Abstract

BACKGROUNDPatients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODSA total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTSOverall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. ConclusionsThe results of the current study identify the topic of sexuality as a p

Published
2016
Full Text
View/download PDF

212. MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

Author

Medicinal Chemistry and Chemical Biology, Sub Chemical pharmacology, Sub Algemeen Scheikunde, Lakshminarayanan, Vani, Supekar, Nitin T, Wei, Jie, McCurry, Dustin B, Dueck, Amylou C, Kosiorek, Heidi E, Trivedi, Priyanka P, Bradley, Judy M, Madsen, Cathy S, Pathangey, Latha B, Hoelzinger, Dominique B, Wolfert, Margreet A, Boons, Geert-Jan, Cohen, Peter A, Gendler, Sandra J, Medicinal Chemistry and Chemical Biology, Sub Chemical pharmacology, Sub Algemeen Scheikunde, Lakshminarayanan, Vani, Supekar, Nitin T, Wei, Jie, McCurry, Dustin B, Dueck, Amylou C, Kosiorek, Heidi E, Trivedi, Priyanka P, Bradley, Judy M, Madsen, Cathy S, Pathangey, Latha B, Hoelzinger, Dominique B, Wolfert, Margreet A, Boons, Geert-Jan, Cohen, Peter A, and Gendler, Sandra J

Published
2016

215. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Author

Geyer, Holly L., primary, Andreasson, Bjorn, additional, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Scherber, Robyn M., additional, Martin, Kari A., additional, Butler, Kristina A., additional, Harrison, Claire N., additional, Radia, Deepti H., additional, Cervantes, Francisco, additional, Kiladjian, Jean‐Jacques, additional, Reiter, Andreas, additional, Birgegard, Gunnar, additional, Passamonti, Francesco, additional, Senyak, Zhenya, additional, Vannucchi, Alessandro M., additional, Paoli, Chiara, additional, Xiao, Zhijian, additional, Samuelsson, Jan, additional, and Mesa, Ruben A., additional

Published
2016
Full Text
View/download PDF

216. Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

Author

Curtis, Kelly K., primary, Ross, Helen J., additional, Garrett, Ashley L., additional, Jizba, Theresa A., additional, Patel, Ajay B., additional, Patel, Samir H., additional, Wong, William W., additional, Halyard, Michele Y., additional, Ko, Stephen J., additional, Kosiorek, Heidi E., additional, and Foote, Robert L., additional

Published
2016
Full Text
View/download PDF

217. MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

Author

Lakshminarayanan, Vani, primary, Supekar, Nitin T., additional, Wei, Jie, additional, McCurry, Dustin B., additional, Dueck, Amylou C., additional, Kosiorek, Heidi E., additional, Trivedi, Priyanka P., additional, Bradley, Judy M., additional, Madsen, Cathy S., additional, Pathangey, Latha B., additional, Hoelzinger, Dominique B., additional, Wolfert, Margreet A., additional, Boons, Geert-Jan, additional, Cohen, Peter A., additional, and Gendler, Sandra J., additional

Published
2016
Full Text
View/download PDF

218. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Author

Scherber, Robyn M., primary, Kosiorek, Heidi E., additional, Senyak, Zhenya, additional, Dueck, Amylou C., additional, Clark, Matthew M., additional, Boxer, Michael A., additional, Geyer, Holly L., additional, McCallister, Archie, additional, Cotter, Mary, additional, Van Husen, Barbara, additional, Harrison, Claire N., additional, and Mesa, Ruben A., additional

Published
2015
Full Text
View/download PDF

220. Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Author

Tibes, Raoul, primary, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Sproat, Lisa, additional, Palmer, Jeanne, additional, Slack, James L., additional, Singh, Devinder, additional, Gebhart, Eileen, additional, Knight, Emily, additional, Hashmi, Shahrukh K., additional, Wilcox, Ryan A, additional, Bogenberger, James M, additional, Mesa, Ruben A., additional, and Al-Kali, Aref, additional

Published
2015
Full Text
View/download PDF

221. Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

Author

Bergsagel, P. Leif, primary, Lacy, Martha Q., additional, Dingli, David, additional, Kumar, Shaji K., additional, Ailawadhi, Sikander, additional, Dispenzieri, Angela, additional, Buadi, Francis, additional, Gertz, Morie A., additional, Stewart, A. Keith, additional, Reeder, Craig B., additional, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Lin, Yi, additional, Chanan-Khan, Asher Alban, additional, and Chesi, Marta, additional

Published
2015
Full Text
View/download PDF

222. Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Author

Scherber, Robyn M., primary, Geyer, Holly, additional, Harrison, Claire N., additional, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Kiladjian, Jean-Jacques, additional, Slot, Stefanie, additional, Xiao, Zhijian, additional, Zweegman, Sonja, additional, Sackmann, Federico, additional, Kerguelen Fuentes, Ana, additional, Hernandez-Maraver, Dolores, additional, Döhner, Konstanze, additional, Radia, Deepti, additional, Muxi, Pablo J., additional, Besses, Carlos, additional, Cervantes, Francisco, additional, Johansson, Peter L., additional, Andreasson, Bjorn, additional, Rambaldi, Alessandro, additional, Barbui, Tiziano, additional, Bonatz, Karin, additional, Reiter, Andreas, additional, Boyer, Francoise, additional, Etienne, Gabriel, additional, Ianotto, Jean-Christophe, additional, Ranta, Dana, additional, Roy, Jean, additional, Cahn, Jean-Yves, additional, Maldonado, Norman I, additional, Barosi, Giovanni, additional, Ferrari, Maria, additional, Gale, Robert Peter, additional, Birgegard, Gunnar, additional, Xu, Zefeng, additional, Zhang, Yu, additional, Sun, Xiujuan, additional, Xu, Junqing, additional, Zhang, Peihong, additional, te Boekhorst, Peter A., additional, Commandeur, Suzan, additional, Schouten, Harry C., additional, Pahl, Heike L, additional, Griesshammer, Martin, additional, Stegelmann, Frank, additional, Lehmann, Thomas, additional, Vannucchi, Alessandro M., additional, Passamonti, Francesco, additional, Samuelsson, Jan, additional, and Mesa, Ruben A., additional

Published
2015
Full Text
View/download PDF

223. Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis

Author

Gowin, Krisstina L., primary, Kosiorek, Heidi E., additional, Dueck, Amylou Constance, additional, Mascarenhas, John, additional, Hoffman, Ronald, additional, Reeder, Craig B., additional, Camoriano, John, additional, Fauble, Veena, additional, Tibes, Raoul, additional, Gano, Katherine, additional, Ghurye, Vineta, additional, Koenig, Patricia, additional, and Mesa, Ruben A., additional

Published
2015
Full Text
View/download PDF

224. Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients

Author

Scherber, Robyn M., primary, Knapper, Steven, additional, Fox, Sonia, additional, Kosiorek, Heidi E., additional, Shah, Marzia, additional, Abdi-Moradi, Sepehr, additional, Mead, Adam J, additional, Dueck, Amylou C., additional, Ailman, Samah, additional, Green, Anthony R, additional, Wood, Marion, additional, Ewing, Joanne, additional, Chen, Fredrick, additional, Coppell, Jason, additional, McMullin, Mary Frances, additional, Geyer, Holly, additional, Mesa, Ruben A., additional, and Harrison, Claire N., additional

Published
2015
Full Text
View/download PDF

226. Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls Using Multivariate Analysis

Author

Anderson, Lesley A., primary, Titmarsh, Glen J., additional, Dueck, Amylou C., additional, Duncombe, Andrew, additional, Mesa, Ruben A., additional, Scherber, Robyn M., additional, Kosiorek, Heidi E., additional, de Vocht, Frank, additional, Clarke, Mike, additional, and McMullin, Mary Frances, additional

Published
2015
Full Text
View/download PDF

227. Regional recurrence in the era of sentinel lymph node biopsy

Author

Linnaus, Maria E., primary, Dueck, Amylou C., additional, Kosiorek, Heidi E., additional, Gray, Richard J., additional, Wasif, Nabil, additional, Northfelt, Donald W., additional, Anderson, Karen S., additional, McCullough, Ann E., additional, Wong, William W., additional, Halyard, Michele Y., additional, Patel, Samir H., additional, and Pockaj, Barbara A., additional

Published
2015
Full Text
View/download PDF

228. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.

Author

Patel, Bhavika K., Hilal, Talal, Covington, Matthew, Zhang, Nan, Kosiorek, Heidi E., Lobbes, Marc, Northfelt, Donald W., and Pockaj, Barbara A.

Abstract

Purpose: To evaluate the performance of contrast-enhanced spectral mammography (CESM) compared to MRI in the assessment of tumor response in breast cancer patients undergoing neoadjuvant systemic therapy (NST).Methods: The institutional review board approved this study. From September 2014 to June 2017, we identified patients with pathologically confirmed invasive breast cancer who underwent NST. All patients had both CESM and MRI performed pre- and post-NST with pathological assessment after surgical management. Size of residual malignancy on post-NST CESM and MRI was compared with surgical pathology. Lin concordance and Pearson correlation coefficient were used to assess agreement. Bland-Altman plots were used to visualize the differences between tumor size on imaging and pathology.Results: Sixty-five patients were identified. Mean age was 52.7 (range 30-76) years. Type of NST included chemotherapy in 53 (82%) and endocrine therapy in 12 (18%). Mean tumor size after NST was 14.6 (range 0-105) mm for CESM and 14.2 mm (range 0-75 mm) for MRI compared with 19.6 (range 0-100) mm on final surgical pathology. Equivalence tests demonstrated that mean tumor size measured by CESM (p = 0.009) or by MRI (p = 0.01) was equivalent to the mean tumor size measured by pathology within − 1 and 1-cm range. Comparing CESM versus MRI for assessment of complete response, the sensitivity was 95% versus 95%, specificity 66.7% versus 68.9%, positive predictive value 55.9% versus 57.6%, and negative predictive value 96.7% versus 96.9% respectively.Conclusions: CESM was comparable to MRI in assessing residual malignancy after completion of NST. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

229. Registered nurse intent to promote physical activity for hospitalised liver transplant recipients.

Author

Pearson, Jocelyn A., Mangold, Kara, Kosiorek, Heidi E., Montez, Morgan, Smith, Diane M., and Tyler, Brenda J.

Subjects
ACADEMIC medical centers, STATISTICAL correlation, LIVER transplantation, RESEARCH methodology, MEDICAL protocols, MOTIVATION (Psychology), NURSES, NURSING, NURSING practice, NURSING services administration, SCALE analysis (Psychology), SURVEYS, TRANSPLANTATION of organs, tissues, etc., MULTIPLE regression analysis, PLANNED behavior theory, PHYSICAL activity, WORK experience (Employment), DESCRIPTIVE statistics, EARLY ambulation (Rehabilitation), HOSPITAL nursing staff, TERTIARY care
Abstract

Aim: To describe how registered nurse work motivation, attitudes, subjective norm and perceived behavioural control influence intention to promote physical activity in hospitalised adult liver transplant recipients. Design: Descriptive study of clinical registered nurses caring for recipients of liver transplant at a tertiary medical centre. Methods: Intent to Mobilise Liver Transplant Recipient Scale, Work Extrinsic and Intrinsic Motivation Scale, and demographics were used to explore registered nurses' work motivation, attitudes, subjective norms, perceived behavioural control and intention to promote physical activity of hospitalised adult liver transplant recipients during the acute postoperative phase. Data analysis included demographics, comparison between scale items and analysis of factors predicting intent to mobilise. Results: Factors predictive of intention to promote physical activity after liver transplant included appropriate knowledge to mobilise patients (R2 = .40) and identification of physical activity as nursing staff priority (R2 = .15) and responsibility (R2 = .03). Discussion/Implications for Nursing Management: When implementing an early mobilisation protocol after the liver transplant, education on effects of physical activity in the immediate postoperative period are essential to promote implementation in practice. Nursing care environment and leadership must be supportive to ensure mobility is a registered nurse priority and responsibility. Nursing managers can leverage results to implement a mobility protocol. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

230. Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection.

Author

Patron, Roberto L., Hartmann, Carlos A., Allen, Sorcha, Griesbach, Cheryl L., Kosiorek, Heidi E., DiBaise, John K., and Orenstein, Robert

Subjects
CLOSTRIDIUM disease treatment, EVALUATION of medical care, FECAL microbiota transplantation, ANALYSIS of variance, HUMAN microbiota, CLOSTRIDIOIDES difficile, CONFIDENCE intervals, FISHER exact test, RESEARCH methodology, STATISTICAL sampling, STATISTICS, DISEASE relapse, VANCOMYCIN, MULTIPLE regression analysis, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, ODDS ratio
Abstract

We retrospectively analyzed a cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota transplantation (FMT) at a tertiary referral center between 2011 and 2014 to determine risk factors for FMT failure. In a multivariate analysis, failure to use an oral vancomycin taper preceding FMT was associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40). [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

231. Predictive Testing for Alzheimer’s Disease

Author

Caselli, Richard J., primary, Marchant, Gary E., additional, Hunt, Katherine S., additional, Henslin, Bruce R., additional, Kosiorek, Heidi E., additional, Langbaum, Jessica, additional, Robert, Jason S., additional, and Dueck, Amylou C., additional

Published
2015
Full Text
View/download PDF

232. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma

Author

Chang, James M., primary, McCullough, Ann E., additional, Dueck, Amylou C., additional, Kosiorek, Heidi E., additional, Ocal, Idris T., additional, Lidner, Thomas K., additional, Gray, Richard J., additional, Wasif, Nabil, additional, Northfelt, Donald W., additional, Anderson, Karen S., additional, and Pockaj, Barbara A., additional

Published
2015
Full Text
View/download PDF

234. Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Author

Mascarenhas, John, Kosiorek, Heidi E., Varricchio, Lilian, Bhave, Rupali, Kuykendall, Andrew T., Komrokji, Rami, Gerds, Aaron T., Palmer, Jeanne M., Gabler, Amelia R., Sandy, Lonette, Migliaccio, Anna Rita, Salama, Mohamed E, Weinberg, Rona Singer, O'Connor-McCourt, Maureen, Tremblay, Gilles, Nadler, Paul I., Dueck, Amylou C., Mesa, Ruben A., and Hoffman, Ronald

Abstract

Mascarenhas: Celgene, Prelude, Galecto, Promedior, Geron, Constellation, and Incyte: Consultancy; Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen, and PharmaEssentia: Other: Research funding (institution). Kuykendall:Blueprint Medicines: Research Funding; BMS: Research Funding; Incyte: Research Funding; Novartis: Research Funding. Komrokji:Jazz: Honoraria, Speakers Bureau; Abbvie: Honoraria; Agios: Speakers Bureau; BMS: Honoraria, Speakers Bureau; Geron: Honoraria; Incyte: Honoraria; Acceleron: Honoraria; Novartis: Honoraria. Gerds:Gilead Sciences: Research Funding; Imago Biosciences: Research Funding; Sierra Oncology: Research Funding; Celgene: Consultancy, Research Funding; Roche/Genentech: Research Funding; CTI Biopharma: Consultancy, Research Funding; Apexx Oncology: Consultancy; AstraZeneca/MedImmune: Consultancy; Pfizer: Research Funding; Incyte Corporation: Consultancy, Research Funding. Migliaccio:Novartis: Research Funding. O'Connor-McCourt:Forbius: Current Employment. Tremblay:Forius: Current Employment. Nadler:Forbius: Consultancy; Nadler Pharma Associates: Current Employment; Symphogen: Consultancy; Iksuda Therapeutics: Consultancy; Tessa Therapeutics: Consultancy. Mesa:Celgene: Research Funding; Genetech: Research Funding; Samus: Research Funding; Promedior: Research Funding; CTI: Research Funding; LaJolla Pharma: Consultancy; Incyte: Research Funding; Sierra Onc: Consultancy; Abbvie: Research Funding; Novartis: Consultancy. Hoffman:Forbius: Consultancy; Abbvie: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Dompe: Research Funding; Protagonist: Consultancy.

Published
2020
Full Text
View/download PDF

235. Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Author

Mazza, Gina L., Mead-Harvey, Carolyn, Mascarenhas, John, Yacoub, Abdulraheem, Hoffman, Ronald, Kosiorek, Heidi E., Prchal, Josef T., Silver, Richard T., Barbui, Tiziano, Dueck, Amylou C., and Mesa, Ruben

Abstract

Mascarenhas: Celgene, Prelude, Galecto, Promedior, Geron, Constellation, and Incyte: Consultancy; Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen, and PharmaEssentia: Other: Research funding (institution). Yacoub:Dynavax: Current equity holder in publicly-traded company; Ardelyx: Current equity holder in publicly-traded company; Cara Therapeutics: Current equity holder in publicly-traded company; Hylapharm: Current equity holder in private company; Incyte: Speakers Bureau; Agios: Honoraria, Speakers Bureau; Novartis: Speakers Bureau; Roche: Other: Support of parent study and funding of editorial support. Hoffman:Protagonist: Consultancy; Forbius: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Dompe: Research Funding. Silver:PharmaEssentia: Speakers Bureau. Mesa:Bristol Myers Squibb: Research Funding; Incyte: Research Funding; AbbVie: Research Funding; Samus Therapeutics: Research Funding; Genentech: Research Funding; CTI BioPharma: Research Funding; Promedior: Research Funding; Sierra Oncology: Consultancy; LaJolla Pharmaceutical Company: Consultancy; Novartis: Consultancy.

Published
2020
Full Text
View/download PDF

236. Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Author

Palmer, Jeanne M., Mead-Harvey, Carolyn, Harrison, Claire, Dueck, Amylou C., Eckert, Ryan, Kosiorek, Heidi E., Muxi, Pablo, Pemmaraju, Naveen, Ruiz Arguelles, Guillermo, Vannucchi, Alessandro M., Gupta, Vikas, Mascarenhas, John, Taylor, Kerry, Gowin, Krisstina L., Geyer, Holly L., Shimoda, Kazuya, Kiladjian, Jean-Jacques, Komatsu, Norio, Kam Li Shan, Grace, Abello, Virginia, Gomez-Almaguer, David, Scherber, Robyn M., Jiang, Qian, Zuo, Xuelan, Huberty, Jennifer, Anderson, Lesley, Langlais, Blake T., Brazeau, Ann, Woehrle, Michelle, Mauro, Michael J., and Mesa, Ruben

Abstract

Background: The COVID pandemic has resulted in significant changes many aspects of daily living. To understand the impact that COVID-19 has had on the myeloproliferative neoplasm (MPN) patient population, we conducted an internet based survey.

Published
2020
Full Text
View/download PDF

240. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.

Author

Scherber, Robyn Marie, Geyer, Holly Lynn, Dueck, Amylou C., Kosiorek, Heidi E., Finazzi, Guido, Cavazzina, Riccardo, Masciulli, Arianna, Scarano, Marco, Vannucchi, Alessandro M., Mesa, Ruben A., and Barbui, Tiziano

Subjects
HEMATOCRIT, POLYCYTHEMIA vera, MYELOPROLIFERATIVE neoplasms, QUALITY of life, PHLEBOTOMY, JANUS kinases
Abstract

Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n = 224) and the MPN-SAF study cohort (n = 645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p = .0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

242. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Author

Scherber, Robyn M., Kosiorek, Heidi E., Senyak, Zhenya, Dueck, Amylou C., Clark, Matthew M., Boxer, Michael A., Geyer, Holly L., McCallister, Archie, Cotter, Mary, Van Husen, Barbara, Harrison, Claire N., and Mesa, Ruben A.

Subjects
*TUMORS, *FATIGUE (Physiology), *EPIDEMIOLOGY of cancer, *SEVERITY of illness index, *SYMPTOMS, *ANXIETY treatment, *THERAPEUTICS, *DIABETES complications, *FATIGUE prevention, *AFFECTIVE disorders, *ANXIETY, *BEHAVIOR, *CHRONIC diseases, *CHRONIC fatigue syndrome, *MENTAL depression, *FIBROMYALGIA, *INTERNET, *QUALITY of life, *SELF-evaluation, *RESTLESS legs syndrome, *COMORBIDITY, *DISEASE complications, *PSYCHOLOGY, BONE marrow cancer
Abstract

Background: Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs.Methods: A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center.Results: Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001).Conclusions: The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

243. IAP antagonists induce anti-tumor immunity in multiple myeloma

Author

Chesi, Marta, Mirza, Noweeda N, Garbitt, Victoria M, Sharik, Meaghen E, Dueck, Amylou C, Asmann, Yan W, Akhmetzyanova, Ilseyar, Kosiorek, Heidi E, Calcinotto, Arianna, Riggs, Daniel L, Keane, Niamh, Ahmann, Gregory J, Morrison, Kevin M, Fonseca, Rafael, Lacy, Martha Q, Dingli, David, Kumar, Shaji K, Ailawadhi, Sikander, Dispenzieri, Angela, Buadi, Francis, Gertz, Morie A, Reeder, Craig B, Lin, Yi, Chanan-Khan, Asher A, Stewart, A Keith, Fooksman, David, and Bergsagel, P Leif

Abstract

Blockade of cIAP1 and cIAP2 induces a tumor cell-autonomous type-I IFN response that activates myeloid cells and potentiates anti-tumor immunity in pre-clinical models and patients with multiple myeloma.

Published
2016
Full Text
View/download PDF

244. A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia

Author

Mascarenhas, John, Kosiorek, Heidi E., Prchal, Josef T., Rambaldi, Alessandro, Berenzon, Dmitriy, Yacoub, Abdulraheem, Harrison, Claire N., McMullin, Mary Frances, Vannucchi, Alessandro M., Ewing, Joanne, O’Connell, Casey L., Kiladjian, Jean-Jacques, Mead, Adam J., Winton, Elliott F., Leibowitz, David S., De Stefano, Valerio, Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Levine, Max F., Ossa, Juan E. Arango, McGovern, Erin, Sandy, Lonette, Salama, Mohamad E., Najfeld, Vesna, Tripodi, Joseph, Farnoud, Noushin, Penson, Alexander V., Weinberg, Rona Singer, Price, Leah, Goldberg, Judith D, Barbui, Tiziano, Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Dueck, Amylou C., and Hoffman, Ronald

Abstract

The goal of therapy for essential thrombocythemia (ET) and polycythemia vera (PV) patients is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for ET and PV patients at high-risk for vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-α (PEG) in treatment naïve, high-risk ET/PV patients. The primary endpoint was complete response (CR) rate at 12 months. A total of 168 patients were treated for a median of 81.0 weeks. CR for HU was 37% and 35% for PEG (p=0.80) at 12 months. At 24/36 months, CR was 20%/17% for HU and 29%/33% for PEG. PEG led to a greater reduction in JAK2V617F at 24 months, but histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms, while grade 3/4 adverse events were more frequent with PEG (46% vs. 28%). At 12 months of treatment there was no significant difference in CR rates between HU and PEG. This study indicates that PEG and HU are both effective treatments for PV and ET. With longer treatment PEG was more effective in normalizing blood counts and reducing driver mutation burden, while HU produced more histopathologic responses. Despite these differences, both agents did not differ in limiting thrombotic events and disease progression in high-risk ET/PV patients. (Funded by the National Cancer Institute, 5P01CA108671-09; clinicaltrials.gov number (NCT01259856)

Published
2022
Full Text
View/download PDF

245. An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy

Author

Kaufman, Adrienne, Kusne, Yael, Klanderman, Molly, Kosiorek, Heidi E., Oliver, Thomas, Gonzalez-Velez, Miguel, McBane, Robert D., Wysokinski, Waldemar E., Houghton, Damon E., and Padrnos, Leslie

Abstract

Introduction: Patients with coronavirus disease 2019 (COVID-19) have an increased risk for venous thromboembolic events. Thrombotic events contribute to the morbidity and mortality associated with COVID-19 infection, and have prompted investigation into strategies for mitigating thrombosis risk in patients hospitalized with COVID-19 infection. Our team reviewed the charts of patients hospitalized with COVID-19 pneumonia at a tertiary hospital in metropolitan Phoenix Arizona between 2020-2021, to assess frequency and efficacy of utilizing a VTE prophylaxis algorithm designed to prevent thrombosis in patients infected with COVID-19.

Published
2021
Full Text
View/download PDF

246. Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Author

Mascarenhas, John, Kosiorek, Heidi E., Bhave, Rupali, Palmer, Jeanne M., Kuykendall, Andrew T., Mesa, Ruben A., Rampal, Raajit, Gerds, Aaron T., Yacoub, Abdulraheem, Pettit, Kristen M., Talpaz, Moshe, Komrokji, Rami S., Kremyanskaya, Marina, Gonzalez, Agapito, Fabris, Frank, Sandy, Lonette, Johnson, Kathryn, Doughtery, Mikaela, McGovern, Erin, Arango Ossa, Juan, Domenico, Dylan, Farnoud, Noushin, Migliaccio, Anna Rita, Salama, Mohamed E, Weinberg, Rona Singer, Kong, Amy, Najfeld, Vesna, Mead-Harvey, Carolyn, Dueck, Amylou C., Varricchio, Lilian, and Hoffman, Ronald

Published
2021
Full Text
View/download PDF

247. Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients

Author

Rosenberg, Shira, Kubas-Meyer, Andrea, Parghi, Neelang, Omans, Nathaniel D., Dusaj, Neville, Chamely, Paulina, Mimitou, Eleni, Dueck, Amylou C., Kosiorek, Heidi E., Weinberg, Rona Singer, Smibert, Peter, Chaligne, Ronan, Landau, Dan A., Hoffman, Ronald, and Nam, Anna S

Abstract

Interferon-alpha (IFN), the first approved immunotherapy for cancer, remains an effective therapy for patients with myeloproliferative neoplasms (MPN). The mechanisms of action of IFN on MPN cells are poorly understood, particularly in patients with CALRmutated (MUT) MPNs, who often exhibit clinical but not molecular responses. Previously, by developing Genotyping of Transcriptomes (GoT) that captures mutation status and single-cell RNA-seq (scRNA-seq) in high-throughput, we observed that CALRmutations led to cell identity-dependent effects on CD34 +cells, including a strong megakaryocytic progenitor (MkP) differentiation bias and fitness. We hypothesized that the IFN effects may be cell identity and mutation status dependent; thus we applied GoT to serial bone marrow aspirates (BM) from 5 patients with CALRmutated ET treated with pegylated-IFN-alfa2a who participated in MPD-RC-111/112 clinical trials.

Published
2021
Full Text
View/download PDF

249. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

Author

Padrnos, Leslie, Ernst, Brenda, Dueck, Amylou C., Kosiorek, Heidi E., Ginos, Brenda F., Toro, Angela, Johnston, Patrick B., Habermann, Thomas M., Leis, Jose F., Mikhael, Joseph R., Nowakowski, Grzegorz S., Colgan, Joseph, Porrata, Luis, Ansell, Stephen M., Witzig, Thomas E., and Reeder, Craig

Published
2018
Full Text
View/download PDF

250. Unplanned implant removal in locally advanced breast cancer.

Author

Anderson, Justin D., Hammond, Jacob B., Kosiorek, Heidi E., Thorpe, Cameron S., Bhangoo, Ronik S., Pockaj, Barbara A., Gray, Richard J., Cronin, Patricia A., Rebecca, Alanna M., Casey, William J., Wong, William W., Keole, Sameer R., Vern‐Gross, Tamara Z., McGee, Lisa A., Halyard, Michele Y., DeWees, Todd A., and Vargas, Carlos E.

Subjects
*MEDICAL device removal, *PHOTON absorptiometry, *METASTASIS, *PLASTIC surgery, *BREAST implants, *COMPARATIVE studies, *POSTOPERATIVE period, *DESCRIPTIVE statistics, *MASTECTOMY, *BREAST tumors
Abstract

Study conducted to determine frequency and timing of unplanned breast implant removal after mastectomy, reconstruction, and postmastectomy radiation (PMRT). From 2010–2017, 52 patients underwent mastectomy, reconstruction, and PMRT. With median follow‐up of 3.1 years, 23 patients (44%) experienced implant removal. Implant removal occurred in 9 (17%) patients before starting PMRT and 14 (27%) patients after starting PMRT. Implant removal rates were similar for hypofractionated PMRT compared with standard fractionation and for proton compared with photon PMRT. Implant removal is common for women undergoing mastectomy and reconstruction followed by PMRT. The risk is clinically significant even before starting radiation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results